The Aptima HSV 1 & 2 nucleic acid amplification test qualitatively detects and differentiates between HSV-1 and HSV-2 on the automated Panther system.
In PLOS this week: regulators of brown adipocyte differentiation, longevity and FOXO3 variants, and more.
The test is the fifth assay on the Solana platform to obtain clearance, and expands the firm's offerings in the women's health market.
The Public Health England lab plans to continue to use Oxford Nanopore's MinIon to help discover novel resistance mutations and elements that influence virulence.
Researchers use the CRISPR/Cas9 gene editing approach to limit herpesviruses replication.
The multiplex qPCR test can detect and discriminate herpes simplex virus 1 and 2 as well as varicella zoster virus, which can be mistaken for HSV in a proportion of cases.
The company issued the Class I recall in February because poor lamination between sample reaction wells led to inaccurate results, but has since resolved the issue.
The platform and the assay were cleared by the US Food and Drug Administration in October and were launched in the US shortly thereafter.
In PNAS this week: single-stranded cytosine deamination in E. coli, characterization of herpes simplex virus-1 microRNAs, and more.
The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.